Why Pharmacotherapy Alone May 'Fail' in Complex TRD (Treatment-Resistant Depression)

Why is Alzheimer’s More Common in Women?

Access the mentioned paper here: Trying to Unravel Why Alzheimer Disease Is More Common in Women By Rita Rubin, MA https://jamanetwork.com/journals/jama/article-abstract/2839498# [https://jamanetwork.com/journals/jama/article-abstract/2839498#]  Access mentioned courses here: Women’s Mental Health Course: https://psychscene.co/41RwJx2 [https://psychscene.co/41RwJx2] Alzheimer’s Disease Course: https://psychscene.co/4vNaeqH [https://psychscene.co/4vNaeqH]  In this episode, Dr Sanil Rege examines why Alzheimer’s disease is more common in women and what this means for clinical assessment, prevention, and treatment. The discussion reviews a 2025 JAMA medical news feature (https://jamanetwork.com/journals/jama/article-abstract/2839498# [https://jamanetwork.com/journals/jama/article-abstract/2839498#]) on sex differences in Alzheimer’s disease and outlines a life-course model showing how sex-related vulnerability may shape disease onset, progression, and clinical expression. This video provides clinicians with a sex-informed clinical framework for assessing Alzheimer’s risk in women through the lens of hormonal transitions, cognitive reserve, and later-life neurodegenerative expression. Chapters: 00:21 Alzheimer’s Disease in Women 02:59 Beyond Longevity 03:40 Survival Differences After Dementia Diagnosis 04:34 Tau Pathology and Steeper Later Decline 06:00 Menopause and Hormonal Vulnerability 08:11 Modifiable Midlife Risk Factors in Women 13:18 A Sex-Informed Life-Course Formulation1 #Alzheimer's #Psychiatry #Dementia

Why the Brain Is Never Really “At Rest”

Here are the links to the papers mentioned: Parkinson’s disease as a somato-cognitive action network disorder Ren et. al. https://psychscene.co/4vQKgmc [https://psychscene.co/4vQKgmc]  The brain’s action-mode network Dosenbach et. al. https://psychscene.co/4ts1pRr [https://psychscene.co/4ts1pRr]  Access mentioned courses here: Advanced Psychiatric Formulation and Strategic Management: https://psychscene.co/4sG214L [https://psychscene.co/4sG214L]  ADHD Masterclass: https://psychscene.co/4sJ1GOS [https://psychscene.co/4sJ1GOS]  In this video, Dr Sanil Rege examines the Action Mode Network as a unifying clinical framework for understanding how the brain regulates action, arousal, body state, and cognition. He explores the counterbalance between action mode and default mode, showing how impaired initiation, hyperarousal, poor state shifting, and social withdrawal may be better understood as disturbances of mode regulation rather than isolated symptom categories. This session provides clinicians with a neurobiological framework for refining psychiatric formulation through the lens of state regulation, brain–body integration, and network-based clinical reasoning. Chapters: 01:32 – Introducing the Action Mode Network 03:17 – The Brain as an Organ Organised for Action 05:48 – Action Mode vs Default Mode 07:18 – Psychiatric Syndromes as Mode-Switching Disorders 09:48– Overcoming the False Dichotomy of Mind and Body 12:25 – The PACES Model in Clinical Formulation 14:48 – Translating State Regulation into Clinical Practice #ActionModeNetwork #Psychiatry #Brain

Have We Been Thinking About Sleep Wrong? (Motor Theory Explained)

Access the mentioned courses here: Sleep And Psychiatry:   https://psychscene.co/46d0T09 ADHD and Sleep Dysfunction: https://psychscene.co/4rrE9Cc In this episode, Dr Sanil Rege explores the "how and why" of sleep by analysing a 2025 Neuron perspective paper (https://pubmed.ncbi.nlm.nih.gov/40961940/) detailing the interplay between sleep, motor circuits, and catecholamine biology. The discussion unpacks the motor theory of sleep, in which sleep control is embedded within somatic and autonomic motor circuits, and the catecholamine hypothesis, which posits that a core biological function of sleep is the inactivation of dopamine, noradrenaline, and adrenaline. This podcast provides clinicians with a neuroscientific framework for understanding sleep as an active state transition involving a global downshift of somatic and autonomic motor systems. #Sleep #Neuropsychiatry #Insomnia

Do ADHD Stimulants ‘Cause’ Psychosis?

Access mentioned course here: https://psychscene.co/46iAaiI In this episode, Consultant Psychiatrist, Dr Sanil Rege examines the complex relationship between ADHD pharmacotherapy and the emergence of psychotic symptoms. By analysing synthesis data from The Lancet Psychiatry (https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(25)00248-2/abstract), the podcast distinguishes between drug-induced events and baseline neurobiological vulnerabilities inherent in ADHD populations. This podcast provides clinicians with a neuroscientific framework for differentiating between protopathic bias and true medication-induced psychotic phenomena, as well as a step-wise screening pathway for risk-guided prescribing using validated at-risk mental state (ARMS) triage tools. To get access to the complete podcast catalog and material like this plus over 150 hours of interactive CPD education on psychiatry, check out The Academy using the link below: https://psychscene.co/45M67jh

Did Ketamine 'Fail' or Are We Asking The Wrong Questions? *Full Study Review*

Access mentioned courses here: Clinical Audit On Cognitive Aspects of Depression:  https://psychscene.co/3Z2EdvH The Aggregation of Marginal Gains as a Philosophy of Clinical Care with Prof Michael Berk:  https://psychscene.co/4rqS62V In this episode, Dr Sanil Rege examines the KARMA-Dep 2 trial, a randomised controlled trial comparing adjunctive serial ketamine infusions to midazolam for patients with Treatment-Resistant Depression (TRD) in an inpatient setting. Based on a JAMA Psychiatry article titled “Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care for Depression,” the discussion explores why statistically insignificant differences between ketamine and psychoactive comparators necessitate a shift in how clinicians evaluate rapid-acting antidepressants, detailing the "wow effect" of early symptomatic drops and the subsequent plateauing of recovery curves. This podcast provides clinicians with a clinical framework for differentiating between acute symptomatic response and long-term functional recovery in TRD. Chapters: 00:22 - The KARMA-Dep 2 Trial Headlines  03:44 - Primary Outcomes: Ketamine vs. Midazolam Results 04:26 - Analysing the Curves: The "Wow Effect" vs. Sustained Recovery 08:50 - Neurobiology of Response vs. Neurobiology of Recovery 09:21 - Why Improvement Stalls: The Role of Neuroadaptation 10:47 - Clinical Implications for Inpatient Care To get access to more materials like this plus over 150 hours of interactive CPD education on psychiatry, check out The Academy using the link below: https://psychscene.co/4rl6pFV